Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Int Ophthalmol. 2020 Jul;40(7):1739-1747. doi: 10.1007/s10792-020-01342-3. Epub 2020 Mar 19.
We aim to study certain histopathological characteristics of the retinoblastoma (RB) tumors in globes with clinically advanced RB, which can be correlated with the high-risk features including: tumor differentiation, growth pattern and focality. We also aim to reclassify the tumor pathologically in the analyzed cases according to the American Joint Committee on Cancer (AJCC) 8th edition in an attempt to compare the validity of this newest classification.
Retrospective study of patients diagnosed with clinical RB of groups D and E during the period: January 2013 to December 2017 at King Khaled Eye Specialist Hospital (KKESH) and King Abdulaziz University Hospital (KAUH). Charts were reviewed for demographic and basic clinical data. Histopathological features (tumor differentiation, growth pattern, focality, seeding, and presence of choroidal invasion (focal versus massive), level of optic nerve (ON) invasion, anterior chamber invasion, scleral and extra-scleral extension, and finally the documented pathological tumors (pT) classification based on the AJCC 7th edition were collected.
We included 146 eyes with advanced retinoblastoma (groups D and E) from 104 patients. Gender distribution was almost equal with 54 males. Median age was 12 months (range 1-96 months), and a mean age was 17.1 ± 15.1 months. No family history was found in the majority (94.2%). Clinically, the most common presenting symptoms: leukocoria (73.3%), squint (33.6%) and least commonly proptosis (2.7%). A total of 106 enucleation specimens were reviewed. Degree of RB differentiation was: well differentiated (18%), moderate (30%), poor (35%), and undifferentiated (17%). The most common high-risk features were ON invasion (68%) with the majority being prelaminar in nature, choroidal invasion (45%) with more than half being massive, iris/trabecular meshwork (TM)/Schlemm's canal invasion (8.5%), and then intra-scleral/extra-scleral extension (5%). Less tumor differentiation doubles the relative risk of massive choroidal invasion (with 95% CI) with a statistically significant P value (P = 0.030). Endophytic RB was associated with vitreous seeding, while exophytic tumors were associated with subretinal seeding (P = 0.001) each. Ten cases with combined ON invasion (pre-laminar) and focal choroidal invasion were reclassified pT2a in the AJCC 8th edition instead of pT2b in the older 7th edition.
Our demographic and basic clinical data for advanced RB are comparable to other similar reports. The tumor growth pattern correlates well with the type of seeding observed in enucleated globes with RB. Less tumor differentiation is a relative risk of massive choroidal invasion. It is advocated to implement the AJCC 8th edition by ocular pathologists worldwide aiming to histopathologically classify the RB tumor in cases for selective adjuvant chemotherapy.
我们旨在研究临床上患有进展期视网膜母细胞瘤(RB)的眼球中 RB 肿瘤的某些组织病理学特征,这些特征与高危特征相关,包括:肿瘤分化、生长模式和局灶性。我们还旨在根据美国癌症联合委员会(AJCC)第 8 版对分析病例中的肿瘤进行病理重新分类,以尝试比较这种最新分类的有效性。
对 2013 年 1 月至 2017 年 12 月在 King Khaled Eye Specialist Hospital(KKESH)和 King Abdulaziz University Hospital(KAUH)诊断为临床 RB 分组 D 和 E 的患者进行回顾性研究。回顾患者的人口统计学和基本临床数据。收集组织病理学特征(肿瘤分化、生长模式、局灶性、播种、脉络膜侵犯(局灶性与弥漫性)、视神经(ON)侵犯程度、前房侵犯、巩膜和眼外延伸,以及最后根据 AJCC 第 7 版记录的病理肿瘤(pT)分类)。
我们纳入了来自 104 名患者的 146 只患有进展期 RB(分组 D 和 E)的眼睛。男女比例几乎相等,男性 54 名。中位年龄为 12 个月(范围 1-96 个月),平均年龄为 17.1±15.1 个月。大多数患者(94.2%)无家族史。临床上,最常见的表现症状为:白瞳(73.3%)、斜视(33.6%)和眼球突出(2.7%)。共回顾了 106 个眼球标本。RB 分化程度为:分化良好(18%)、中度(30%)、差(35%)和未分化(17%)。最常见的高危特征为 ON 侵犯(68%),其中大多数为前鞘内侵犯;脉络膜侵犯(45%),其中超过一半为弥漫性侵犯;虹膜/小梁网/施莱姆氏管(TM)侵犯(8.5%),然后是巩膜内/外侵犯(5%)。肿瘤分化程度较差会使弥漫性脉络膜侵犯的相对风险增加一倍(95%CI),且 P 值具有统计学意义(P=0.030)。内生型 RB 与玻璃体内播种有关,而外生型肿瘤与视网膜下播种有关(P=0.001)。10 例同时伴有 ON 侵犯(前鞘内)和局灶性脉络膜侵犯的病例,根据 AJCC 第 8 版被重新分类为 pT2a,而不是第 7 版的 pT2b。
我们的进展期 RB 的人口统计学和基本临床数据与其他类似报告相当。肿瘤生长模式与眼球中观察到的播种类型密切相关。肿瘤分化程度较差是弥漫性脉络膜侵犯的相对风险。我们提倡全世界的眼病理学家实施 AJCC 第 8 版,旨在对 RB 肿瘤进行组织病理学分类,以便为选择性辅助化疗选择病例。